This Healthcare Company Believes Its GLP-1 Pill Could Be "Next in Line" After Novo Nordisk and Eli Lilly. Its Valuation Is a Fraction of Theirs.

Novo Nordisk and Eli Lilly are the two leading companies in the GLP-1 drug race right now. But the field is inevitably going to get bigger as more drugmakers are researching obesity drugs in the hopes of securing some significant market share, in what's becoming the next big growth opportunity in healthcare. The good news is that some smaller stocks may have more potential upside if they obtain approval for their products. There is, of course, the risk that they don't get there. But one company that belie ...